| 000 | 01834 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518014456.0 | ||
| 264 | 0 | _c20190522 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1099-1069 | ||
| 024 | 7 |
_a10.1002/hon.2572 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPrusila, Roosa Enni Inkeri | |
| 245 | 0 | 0 |
_aTreatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16). _h[electronic resource] |
| 260 |
_bHematological oncology _cApr 2019 |
||
| 300 |
_a136-142 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Substitution |
| 650 | 0 | 4 |
_aEpirubicin _xadministration & dosage |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHeart Diseases _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMatched-Pair Analysis |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aProgression-Free Survival |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRituximab _xadministration & dosage |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aPeroja, Pekka | |
| 700 | 1 | _aJantunen, Esa | |
| 700 | 1 | _aTurpeenniemi-Hujanen, Taina | |
| 700 | 1 | _aKuittinen, Outi | |
| 773 | 0 |
_tHematological oncology _gvol. 37 _gno. 2 _gp. 136-142 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hon.2572 _zAvailable from publisher's website |
| 999 |
_c29202220 _d29202220 |
||